口腔崩解型奥氮平综述：有效性、患者偏好、依从性及其他特性
Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.
作者信息
Montgomery William, Treuer Tamas, Karagianis Jamie, Ascher-Svanum Haya, Harrison Gavan
机构信息
Global Health Outcomes, Eli Lilly and Company, Sydney, Australia.
出版信息
Patient Prefer Adherence. 2012;6:109-25. doi: 10.2147/PPA.S27344. Epub 2012 Feb 1.
Abstract
Orally disintegrating olanzapine (ODO) is a rapid-dissolving formulation of olanzapine which disintegrates in saliva almost immediately, developed as a convenient and adherence-enhancing alternative to the standard olanzapine-coated tablet (SOT). Clinical studies, which form the basis of this review, have shown ODO and SOT to have similar efficacy and tolerability profiles. However, ODO appears to have a number of advantages over SOT in terms of adherence, patient preference, and reduction in nursing burden. Overall, the existing clinical data suggests that compared to SOT, ODO is not only well-suited for difficult-to-treat, agitated, and/or nonadherent patients but, due to its potential ability to improve adherence and greater patient preference, may also be an appropriate formulation for the majority of patients for which olanzapine is the antipsychotic of choice.
摘要
口腔崩解型奥氮平（ODO）是奥氮平的一种速溶制剂，几乎能立即在唾液中崩解，它是作为标准奥氮平包衣片（SOT）的一种方便且能提高依从性的替代剂型而开发的。构成本综述基础的临床研究表明，ODO和SOT具有相似的疗效和耐受性特征。然而，ODO在依从性、患者偏好以及减轻护理负担方面似乎比SOT有许多优势。总体而言，现有临床数据表明，与SOT相比，ODO不仅适用于难治性、躁动和/或不依从的患者，而且由于其潜在的提高依从性的能力和更高的患者偏好性，对于大多数将奥氮平作为首选抗精神病药物的患者来说，也可能是一种合适的剂型。
相似文献
1
Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.口腔崩解型奥氮平综述：有效性、患者偏好、依从性及其他特性
Patient Prefer Adherence. 2012;6:109-25. doi: 10.2147/PPA.S27344. Epub 2012 Feb 1.
2
Clinical utility of orally disintegrating olanzapine in Chinese patients with schizophrenia: a review of effectiveness, patient preference, adherence, and other properties.口服崩解型奥氮平在中国精神分裂症患者中的临床应用：疗效、患者偏好、依从性及其他特性综述
Neuropsychiatr Dis Treat. 2014 Feb 19;10:355-9. doi: 10.2147/NDT.S39055. eCollection 2014.
3
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.阿立哌唑口崩片治疗中国精神分裂症的成本效果分析。
Expert Rev Pharmacoecon Outcomes Res. 2020 Oct;20(5):549-557. doi: 10.1080/14737167.2020.1807331. Epub 2020 Sep 23.
4
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.一项关于舌下含服奥氮平口崩片与口服奥氮平对体重指数影响的随机对照试验：鸭嘴兽研究
Schizophr Res. 2009 Aug;113(1):41-8. doi: 10.1016/j.schres.2009.05.024. Epub 2009 Jun 16.
5
Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.几种非典型抗精神病药的口腔崩解片与标准口服片剂在美国治疗精神分裂症的成本效益比较。
J Med Econ. 2012;15(3):531-47. doi: 10.3111/13696998.2012.662923. Epub 2012 Feb 21.
6
Olanzapine orally disintegrating tablet: a review of efficacy and compliance.奥氮平口腔崩解片：疗效与依从性综述
CNS Neurosci Ther. 2008 Fall;14(3):203-14. doi: 10.1111/j.1755-5949.2008.00053.x.
7
Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.奥氮平在中国精神分裂症一线治疗中的成本效益
J Med Econ. 2019 May;22(5):439-446. doi: 10.1080/13696998.2019.1580714. Epub 2019 Mar 5.
8
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.一项关于口服与口服速释奥氮平治疗 16 周体重变化相关因素的探索性分析：PLATYPUS 研究。
Int J Clin Pract. 2010 Oct;64(11):1520-1529. doi: 10.1111/j.1742-1241.2010.02485.x.
9
Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia.奥氮平口腔崩解片在精神分裂症患者中的溶出曲线、耐受性及可接受性
Can J Psychiatry. 2002 Oct;47(8):771-4. doi: 10.1177/070674370204700809.
10
Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients.奥氮平口崩片与标准奥氮平片相比在急性治疗的精神科患者中的有效性及药物接受度
Patient Prefer Adherence. 2007 Dec 20;1:19-27. doi: 10.2147/ppa.s2300.
引用本文的文献
1
Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine.卡利拉嗪口崩片：卡利拉嗪的一种新剂型。
Pharmacopsychiatry. 2024 Jul;57(4):180-185. doi: 10.1055/a-2291-7130. Epub 2024 May 6.
2
Pharmacotechnical and analytical preformulation studies for cannabidiol orodispersible tablets.大麻二酚口腔崩解片的药剂学和分析前制剂研究
Saudi Pharm J. 2021 Sep;29(9):1029-1042. doi: 10.1016/j.jsps.2021.07.012. Epub 2021 Jul 17.
3
The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature.奥氮平在姑息医学中作为止吐药的应用：文献系统评价。
BMC Palliat Care. 2020 Apr 22;19(1):56. doi: 10.1186/s12904-020-00559-4.
4
Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.以患者为中心的药品设计——对药物依从性的影响。
Pharmaceutics. 2020 Jan 3;12(1):44. doi: 10.3390/pharmaceutics12010044.
5
Characterization and in vivo efficacy of a heptapeptide ODT formulation for the treatment of neurogenic bladder dysfunction.一种用于治疗神经原性膀胱功能障碍的七肽 ODT 制剂的特征描述和体内疗效。
Int J Pharm. 2018 Jan 30;536(1):397-404. doi: 10.1016/j.ijpharm.2017.11.036. Epub 2017 Nov 28.
6
Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder.奥氮平口腔崩解片与标准口服片剂治疗精神分裂症或双相情感障碍不依从患者的临床疗效比较
Patient Prefer Adherence. 2017 Jun 6;11:1019-1025. doi: 10.2147/PPA.S124581. eCollection 2017.
7
Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations.以患者为中心的药物设计以提高药物的可接受性：儿科和老年人群的异同
Drugs. 2014 Oct;74(16):1871-1889. doi: 10.1007/s40265-014-0297-2.
8
Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.载有奥氮平的壳聚糖纳米颗粒的鼻内给药
AAPS PharmSciTech. 2014 Dec;15(6):1598-602. doi: 10.1208/s12249-014-0189-5. Epub 2014 Aug 21.
9
Alternative delivery systems for agents to treat acute agitation: progress to date.治疗急性激越的药物的替代给药系统：最新进展。
Drugs. 2013 Nov;73(16):1783-92. doi: 10.1007/s40265-013-0130-3.
10
Stability of benzocaine formulated in commercial oral disintegrating tablet platforms.商业化口腔崩解片平台中苯佐卡因的稳定性。
AAPS PharmSciTech. 2013 Dec;14(4):1333-40. doi: 10.1208/s12249-013-0015-5. Epub 2013 Aug 30.
本文引用的文献
1
Olanzapine oro-dispersible (Velotab TM ) - an alternative to depot?奥氮平口腔崩解片（再普乐 TM ）——一种替代长效针剂的选择？
Int J Psychiatry Clin Pract. 2002;6(3):163-5. doi: 10.1080/136515002760276090.
2
Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression.口腔崩解型与普通奥氮平片对体重、进食行为、血糖和血脂指标以及胃肠激素的影响：双相抑郁门诊患者的随机开放对照研究
Ann Clin Psychiatry. 2011 Aug;23(3):193-201.
3
Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.首发精神分裂症患者抗精神病药物治疗的依从性：一项为期六个月的自然随访研究。
Schizophr Res. 2011 Aug;130(1-3):176-81. doi: 10.1016/j.schres.2011.04.030. Epub 2011 Jun 1.
4
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.奥氮平治疗精神分裂症和双相情感障碍后体重增加和代谢变量的变化。
Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000.
5
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).在 18154 名精神分裂症患者的真实世界应用中，齐拉西酮与奥氮平相关的死亡率比较：齐拉西酮心脏结局观察研究（ZODIAC）。
Am J Psychiatry. 2011 Feb;168(2):193-201. doi: 10.1176/appi.ajp.2010.08040484. Epub 2010 Nov 1.
6
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.一项关于口服与口服速释奥氮平治疗 16 周体重变化相关因素的探索性分析：PLATYPUS 研究。
Int J Clin Pract. 2010 Oct;64(11):1520-1529. doi: 10.1111/j.1742-1241.2010.02485.x.
7
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.一项多中心、随机、交叉研究比较了奥氮平口崩片与普通口服片剂在患者中的偏好。
World J Biol Psychiatry. 2010 Oct;11(7):894-903. doi: 10.3109/15622975.2010.505663.
8
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.比较肌内注射奥氮平、口腔崩解片奥氮平、口服利培酮溶液和氟哌啶醇肌内注射在台湾急性精神科病房急性激越管理中的效果。
J Clin Psychopharmacol. 2010 Jun;30(3):230-4. doi: 10.1097/JCP.0b013e3181db8715.
9
The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs.治疗精神分裂症时，因任何原因停药的所需人数：全球地理和研究设计的一致性。
Pharmacopsychiatry. 2010 May;43(3):81-5. doi: 10.1055/s-0029-1242816. Epub 2009 Dec 16.
10
Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.口服崩解片和口服标准奥氮平片在 12 名健康男性中同样能升高稳态模型评估的胰岛素抵抗指数和血浆甘油三酯水平：一项随机交叉研究。
J Clin Psychiatry. 2010 Sep;71(9):1205-11. doi: 10.4088/JCP.08m04654yel. Epub 2010 Apr 20.
Zotero 插件